Psychiatric drug discovery is in a state of flux in 2013. Significant reductions in investment across large pharmaceutical companies combined with shifts in academic funding have led to a necessary new world of opportunity based around collaborations, partnerships and business operating models. These new modes of research and drug development will only bring future success by learning from past failures and we will highlight some areas for consideration. Finally, in this apparent era of doom there are some success stories to cheer, which suggest that there will be future advances in treatment for the large patient population whose lives are spent in the shadow of mental illness.
Skip Nav Destination
Feature| June 01 2013
The road ahead: A perspective of drug discovery in psychiatry in 2013 from inside an evolving industry
John Dunlop ;
Biochem (Lond) (2013) 35 (3): 24–29.
- Views Icon Views
- PDF LinkPDF
- Share Icon Share
John Dunlop, Nicholas J. Brandon; The road ahead: A perspective of drug discovery in psychiatry in 2013 from inside an evolving industry. Biochem (Lond) 1 June 2013; 35 (3): 24–29. doi: https://doi.org/10.1042/BIO03503024
Download citation file: